Omnipod® 5 Automated Insulin Delivery System

Register your interest

Omnipod® 5
Tubeless, automated insulin adjustments

Omnipod® 5, the first wearable, tubeless, hybrid closed loop system integrated with Dexcom G6, is now CE marked for people with type 1 diabetes aged 2 years and older.

The Omnipod® 5 System works with the Dexcom G6 Continuous Glucose Monitoring System to continuously adapt and automatically deliver basal insulin according to your personal needs.

3 Simple Parts

To enjoy Automated Insulin Delivery with the Omnipod® 5 System

Omnipod 5 controller*

Take full control of the Pod from the Omnipod® 5 Controller

Pod

Tubeless, wearable and waterproof, but now enhanced with SmartAdjustTM technology

Dexcom® G6 CGM  System 

With SmartAdjust™ technology, Omnipod® 5 and the Dexcom G6 CGM are in constant communication, enabling automatic insulin adjustments to help improve time in range

A separate prescription is required for the Dexcom G6 CGM. The Dexcom G6 is sold separately. The Dexcom G6 app is required for use with the Omnipod 5 System.

Always adjusting, so you don’t have to

Omnipod® 5* with SmartAdjust™ technology automatically increases, decreases, or pauses insulin delivery, every five minutes, to your personal needs which may help prevent highs and lows.

Want to be kept updated on the latest on Omnipod® 5?

Looking for more information about Omnipod® 5?

Check out the Omnipod 5 FAQS 

Risk Statement
The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoRapid®, Humalog®, and Admelog®.
The Omnipod 5 Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values. The Omnipod 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value.

WARNING: SmartAdjust technology should NOT be used by anyone under the age of 2 years old. SmartAdjust technology should also NOT be used in people who require less than 6 units of insulin per day as the safety of the technology has not been evaluated in this population.
The Omnipod 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod 5 System according to instructions, are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit www.omnipod.com/safety for additional important safety information.

WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.

Regional Disclaimer

Are you a resident of the United Kingdom?

Yes No

The content of the webpage that you are about to access is exclusively reserved for residents of the United Kingdom.

If you are a resident of the United Kingdom, please click 'Yes' to continue. If not, please click 'No' to exit and do not access the web pages. If you selected this country/language in error, you can go back to the previous page and select your country/language.

Thank you.